NCT05602766View on ClinicalTrials.gov

Ngenla Subcutaneous Injection Special Investigation

Active, not recruitingOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

April 6, 2029

Study Completion Date

April 6, 2029

Conditions

Growth Hormone Deficiency Without Epiphyseal Closure

Interventions

DRUG

NGENLA (Somatrogon)

Dosage, Frequency: Refer to the latest package insert.

Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT05602766 - Ngenla Subcutaneous Injection Special Investigation | Biotech Hunter | Biotech Hunter